What patients and caregivers need to know about the latest NCCN guidance and DPD testing before treatment for anal cancer.
What is NCCN?
The National Comprehensive Cancer Network is a non-profit dedicated to cancer care. The NCCN creates national guidelines that are followed in the United States.
What’s DPD and why does it matter?
- 5-Fluorouracil (5-FU) and capecitabine are cornerstone chemotherapy drugs for anal cancer.
- They are normally broken down by an enzyme called DPD (DPD is short for dihydropyrimidine dehydrogenase).
- About 3–8 % of people inherit “slow-working” DPD genes (DPYD variants). If DPD doesn’t do its job, even a standard dose of 5-FU can build up and cause severe mouth sores, stomach problems, low white‑blood‑cell counts, or in rare cases -- life‑threatening reactions.
Think of DPD as the body’s garbage disposal for these drugs. If the disposal is jammed, the sink overflows.
Can doctors test for this problem?
Yes. A simple blood test or cheek swab can check the common DPYD gene variants linked to high risk. Typically results are available within a few days.
What do the 2025 NCCN Anal Carcinoma Guidelines say?
- The April 2025 update tells doctors to “consider DPYD genotyping or phenotyping and discuss the pros and cons with patients before starting any fluoropyrimidine.”
- It is *not* a blanket rule. The panel stops short of saying everyone must be tested. Instead, testing is described as a “clinically actionable consideration.”
- Similar wording now appears in the colorectal, rectal, and small‑bowel cancer chapters, showing a consistent, but still optional stance.
What we do and do not know
What we know:
- Testing finds most high‑risk patients and cuts severe side‑effects by roughly half when doses are adjusted.
- Same‑day genotyping is available in some big centers.
- European health systems find testing cost‑effective when lab costs are low.
What we still don’t know:
- Anal‑cancer–specific studies are small; we can’t yet prove testing improves survival or quality of life in this cancer.
- Many hospitals still need to send the sample out, adding a 5‑ to 7‑day delay.
- U.S. insurance coverage and real‑world costs are uneven.
Practical takeaway for patients and families
1) Ask the question of your health care professional. It’s reasonable to say, “Should I be tested for DPD deficiency before I start 5-FU?”
2) Understand the trade‑offs. Testing can lower the risk of serious side‑effects of treatment, but it may delay the start of treatment if your center can’t provide a rapid test.
3) Dose‑reduction is possible. If you carry a DPYD variant, doctors can start at a lower dose or choose a different drug.
4) Monitoring still matters. Whether or not you get tested, early lab checks and clear reporting of symptoms (mouth sores, diarrhea, fever) are critical.
SUMMARY
The current NCCN guidelines encourage a conversation, but stop short of a universal mandate. There is not enough evidence currently to prove that routine, across‑the‑board DPD testing benefits every anal‑cancer patient, especially when test access and turnaround times vary.
Until larger studies give clearer answers, decisions should be personalized. This balances safety, timing, and local resources. If you’re about to start chemotherapy treatment for anal cancer, talk with your oncology team about whether DPD testing makes sense for you.
*This post is for education only and should not replace medical advice from your care team.*
References:
National Comprehensive Cancer Network. (2025 May). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Anal Carcinoma: Version 4.2025 — May 30, 2025.
